InsidersTradesSigma
Medartis Holding AG Stock: price and directors' dealings · Switzerland · SIX SER
Follow the Medartis Holding AG stock price and the full directors' dealings record of the company, a publicly traded company based in Switzerland. Shares trade on CH CH, under the supervision of SIX SER. Operating in the Healthcare & Pharma sector, Medartis Holding AG has published 75 insider filings. Market capitalisation: €1.1bn. The latest transaction was reported on 29 April 2026 (Purchase). Among the most active insiders: Anonymous (Non-executive member of the board of directors). Every trade is free.
75
Insider Decl.
0
Thresholds
€13m
43 ops.
Buy Volume
€24m
32 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Medartis Holding AG Buy (bullish), based on 3 analysts. Average price target: CHF 95.00.
24Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 17,678 of 26,211 companies
40.3
score / 100
Value31
Quality50
FCF yld0.8%
Earn yld0.7%
EV/EBITDA28.4x
ROE3.4%
Gross mgn76%
Net mgn3.1%
Debt/EBITDA3.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 29 April 2026
Declarations75 total
●
Anonymous (a non-executive member of the board of directors)
a non-executive member of the board of directorsExecutives(filed)
372 shares@ CHF 67.150.0028% mcap3.5% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q4T000D6
Ideal exit: 24 Jan 2027 (T+270)
●
Anonymous (Non-executive member of the board of directors)
Non-executive member of the board of directorsExecutives
372 shares@ CHF 67.150.0028% mcap0.1% of flowSIX:T1Q4T000D6
Ideal exit: 24 Jan 2027 (T+270)
●
Anonymous (a non-executive member of the board of directors)
a non-executive member of the board of directorsExecutives(filed)
558 shares@ CHF 67.150.0042% mcap5.3% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q4R000J5
Ideal exit: 22 Jan 2027 (T+270)
●
Anonymous (a non-executive member of the board of directors)
a non-executive member of the board of directorsExecutives(filed)
1,489 shares@ CHF 67.150.011% mcap14.0% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q4R000K3
Ideal exit: 22 Jan 2027 (T+270)
●
Anonymous (Non-executive member of the board of directors)
Non-executive member of the board of directorsExecutives
1,489 shares@ CHF 67.150.011% mcap0.3% of flowSIX:T1Q4R000K3
Ideal exit: 22 Jan 2027 (T+270)
●
Anonymous (Non-executive member of the board of directors)
Non-executive member of the board of directorsExecutives
558 shares@ CHF 67.150.0042% mcap0.1% of flowSIX:T1Q4R000J5
Ideal exit: 22 Jan 2027 (T+270)
●
Anonymous (a non-executive member of the board of directors)
a non-executive member of the board of directorsExecutives(filed)
744 shares@ CHF 67.150.0056% mcap7.0% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q4O000I0
Ideal exit: 19 Jan 2027 (T+270)
●
Anonymous (a non-executive member of the board of directors)
a non-executive member of the board of directorsExecutives(filed)
7,445 shares@ CHF 67.150.056% mcap70.2% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q4O000J8
Ideal exit: 19 Jan 2027 (T+270)
●
Anonymous (Non-executive member of the board of directors)
Non-executive member of the board of directorsExecutives
7,445 shares@ CHF 67.150.056% mcap1.6% of flowSIX:T1Q4O000J8
Ideal exit: 19 Jan 2027 (T+270)
●
Anonymous (Non-executive member of the board of directors)
Non-executive member of the board of directorsExecutives
744 shares@ CHF 67.150.0056% mcap0.2% of flowSIX:T1Q4O000I0
Ideal exit: 19 Jan 2027 (T+270)
●
Anonymous (Executive member of the board of directors / member of senior management)
Executive member of the board of directors / member of senior managementExecutives
700 shares@ CHF 88.012.5% of flowSIX:T1PCT00022
●
Anonymous (Executive member of the board of directors / member of senior management)
Executive member of the board of directors / member of senior managementExecutives
1,139 shares@ CHF 90.004.1% of flowSIX:T1PCT00014
●
Anonymous (Non-executive member of the board of directors)
Non-executive member of the board of directorsExecutives
6,300 shares@ CHF 79.201.6% of flowSIX:T1PCC000B8
●
Anonymous (Non-executive member of the board of directors)
Non-executive member of the board of directorsExecutives
18,939 shares@ CHF 79.204.8% of flowSIX:T1PCC000D4
Ideal exit: 8 Sept 2026 (T+270)
●
Anonymous (Non-executive member of the board of directors)
Non-executive member of the board of directorsExecutives
5,657 shares@ CHF 79.201.4% of flowSIX:T1PCC000A0
●
Anonymous (Non-executive member of the board of directors)
Non-executive member of the board of directorsExecutives
8,333 shares@ CHF 79.202.1% of flowSIX:T1PCC000P8
●
Anonymous (Non-executive member of the board of directors)
Non-executive member of the board of directorsExecutives
18,939 shares@ CHF 79.204.8% of flowSIX:T1PCC000C6
●
Anonymous (Non-executive member of the board of directors)
Non-executive member of the board of directorsExecutives
6,313 shares@ CHF 79.201.6% of flowSIX:T1PCC00085
●
Anonymous (Non-executive member of the board of directors)
Non-executive member of the board of directorsExecutives
17,576 shares@ CHF 79.204.5% of flowSIX:T1PCC00093
●
Anonymous (Non-executive member of the board of directors)
Non-executive member of the board of directorsExecutives
126,276 shares@ CHF 79.2031.9% of flowSIX:T1PCB000A1
●
Anonymous (Non-executive member of the board of directors)
Non-executive member of the board of directorsExecutives
715 shares@ CHF 88.00770.2% of flowSIX:T1PC300058
●
Anonymous (Non-executive member of the board of directors)
Non-executive member of the board of directorsExecutives
1,441 shares@ CHF 85.16490.4% of flowSIX:T1PBS00075
●
Anonymous (Executive member of the board of directors / member of senior management)
Executive member of the board of directors / member of senior managementExecutives
382 shares@ CHF 67.26651.0% of flowSIX:T1PAR00079
Ideal exit: 24 Jul 2026 (T+270)
●
Anonymous (Executive member of the board of directors / member of senior management)
Executive member of the board of directors / member of senior managementExecutives
148 shares@ CHF 67.26650.4% of flowSIX:T1PAM00021
Ideal exit: 19 Jul 2026 (T+270)
●
Anonymous (Executive member of the board of directors / member of senior management)
Executive member of the board of directors / member of senior managementExecutives
74 shares@ CHF 67.26650.2% of flowSIX:T1PAL000C7
Ideal exit: 18 Jul 2026 (T+270)
25 of 75 declarations
About Medartis Holding AG
Medartis Holding AG is a Swiss medical device company listed on the SIX Swiss Exchange (SMI/SPI) in Switzerland. Founded in 1997 and headquartered in Basel, the company has built a focused franchise in orthopaedic surgical fixation, with particular strength in the craniomaxillofacial (CMF) segment and in solutions for upper and lower extremities. Its roots are tied to Switzerland’s precision manufacturing tradition, and its business model has been shaped around proprietary implant systems, surgeon-centric product design, and a strong clinical orientation. ([stockanalysis.com](https://stockanalysis.com/quote/swx/MED/company/?utm_source=openai)) Medartis develops, manufactures, and sells implant solutions used to stabilise and repair bone fractures. Its portfolio includes plates, screws, instruments, and related systems designed for trauma and reconstructive surgery. The company’s differentiation lies in the breadth of its orthopaedic offering, the technical quality of its products, and the usability of its systems in the operating room. From an investor perspective, Medartis combines a Swiss headquarters with an international commercial footprint, allowing it to pair “Swiss precision” with global reach across multiple healthcare markets. ([medartis.com](https://medartis.com/company/?utm_source=openai)) Competitive positioning is important. Medartis operates in a demanding segment of the medical technology market, where large global medtech groups compete for hospital access, surgeon preference, and product adoption. Within that landscape, Medartis stands out as a specialist rather than a broad-based orthopaedics conglomerate. This narrower focus can be an advantage: it supports technical depth, closer customer relationships, and a more targeted innovation pipeline. It also means the company’s market narrative is typically centred on share gains in niche indications, product launches, and geographic expansion rather than on scale alone. ([medartis.com](https://medartis.com/company/?utm_source=openai)) Recent developments have reinforced that growth profile. In March 2026, Medartis reported full-year 2025 sales of CHF 269.3 million and highlighted improved operating profitability, while also describing an organisational shift toward a more decentralised, multi-brand structure. In April 2026, shareholders strongly approved the board’s proposals at the AGM. The market had also paid attention to management and board-related transactions disclosed through the Swiss disclosure framework in late 2025, which is relevant for investors following SIX-regulated reporting and governance signals. Overall, Medartis presents as a niche Swiss medtech name with international ambitions, supported by operating momentum and a disciplined strategic focus. ([eqs-news.com](https://www.eqs-news.com/news/ad-hoc/medartis-builds-on-momentum-with-16-organic-sales-growth-and-core-ebitda-margin-exceeding-18/2065ea62-13b4-40e4-a62c-acc32c2b9cd3?utm_source=openai))
